Insulet

$295.39 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Insulet

Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.

Stock Analysis

last close $297.56
1-mo return -2.2%
3-mo return -0.8%
avg daily vol. 371.4T
52-week high 324.81
52-week low 218.28
market cap. $20.8B
forward pe 256.6
annual div. -
roe -5.4%
ltg forecast -
dividend yield -
annual rev. $1.0B
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe